The continuously increasing global cancer burden acts as the strongest primary driver of the liquid biopsy market through a direct cause-and-effect diagnostic demand chain. As cancer incidence rises due to aging populations, sedentary lifestyles, environmental exposure, and genetic risk, the volume of patients requiring early detection, molecular profiling, and therapy monitoring expands sharply. Conventional tissue biopsies are invasive, costly, and difficult to repeat, especially in advanced or fragile patients. This limitation directly accelerates demand for liquid biopsy, which enables safe, repeatable, and real-time tumor assessment through circulating biomarkers. As oncology care shifts toward precision medicine and longitudinal disease monitoring, liquid biopsy adoption increases rapidly across diagnostics, prognosis, and treatment response tracking.

Industry Overview

According to SkyQuest Technology “Global Liquid Biopsy Market” By Product (Assay Kits, Instruments), By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA), By Technology, By Region - Industry Forecast 2025-2032,” Global liquid biopsy market is projected to grow at a CAGR of over 10.7% by 2032, on account of urgent need for automating quantified data. Rapid technological advancement in next-generation sequencing, digital PCR, and bioinformatics acts as a critical growth-enabling factor for the liquid biopsy market. As sequencing throughput improves and costs decline, ultra-low concentrations of circulating tumor DNA can be detected with greater accuracy and reliability.

Top 10 Global Liquid Biopsy Companies

1. Guardant Health, Inc.

Guardant Health, Inc. is a global pioneer in liquid biopsy and precision oncology, transforming cancer care through advanced blood-based genomic testing. Founded in 2012 and headquartered in Palo Alto, California, the company specializes in detecting and monitoring cancer through circulating tumor DNA (ctDNA) analysis. Its core offerings include Guardant360® CDx, GuardantOMNI®, and LUNAR® early cancer detection tests, widely used for therapy selection and disease monitoring. Guardant Health plays a critical role in advancing non-invasive cancer diagnostics, supporting real-time treatment decisions and accelerating personalized oncology worldwide.

2. Natera, Inc.

Natera, Inc. is a global leader in cell-free DNA–based diagnostics, playing a critical role in shaping the liquid biopsy landscape across oncology, women’s health, and organ transplantation. Founded in 2004 and headquartered in Austin, Texas, the company pioneered ultra-sensitive molecular testing through its proprietary NATUS™ technology platform. In oncology, Natera’s Signatera™ test is widely used for minimal residual disease detection, treatment response monitoring, and recurrence surveillance across multiple cancer types. Through its expanding global testing infrastructure and precision medicine focus, Natera continues to drive adoption of personalized, non-invasive diagnostics worldwide.

3. Exact Sciences Corporation

Exact Sciences Corporation is a global molecular diagnostics company renowned for advancing early cancer detection through non-invasive testing technologies, with a growing footprint in the liquid biopsy market. Founded in 1995 and headquartered in Madison, Wisconsin, the company is best known for its Cologuard® portfolio and rapidly expanding blood-based cancer screening programs. Exact Sciences leverages advanced genomics, biomarkers, and next-generation sequencing to enable early, accurate detection and ongoing disease monitoring. Through continuous R&D investment and strategic collaborations, the company is strengthening its position in precision oncology and population-scale cancer screening worldwide.

4. GRAIL, Inc.

GRAIL, Inc. is a leading biotechnology company dedicated to transforming cancer care through multi-cancer early detection using blood-based liquid biopsy technology. Founded in 2015 and headquartered in Menlo Park, California, the company pioneered large-scale population cancer screening through its flagship Galleri® test, which can detect signals from more than 50 cancer types from a single blood draw. By combining cell-free DNA analysis with advanced machine learning and methylation profiling, GRAIL is driving a paradigm shift toward earlier, more accurate cancer diagnosis and improved long-term survival outcomes worldwide.

5. Foundation Medicine, Inc.

Foundation Medicine, Inc., a subsidiary of Roche, is a leading global provider of comprehensive genomic profiling that plays a vital role in the liquid biopsy and precision oncology ecosystem. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company specializes in next-generation sequencing–based testing to identify actionable cancer mutations from both tissue and blood samples. Its flagship FoundationOne® Liquid CDx test enables non-invasive, pan-tumor genomic profiling to guide targeted therapy selection. Through strong clinical validation, regulatory approvals, and global partnerships, Foundation Medicine continues to advance personalized cancer treatment worldwide.

6. Biocept, Inc.

Biocept, Inc. is a molecular diagnostics company specializing in liquid biopsy technologies for non-invasive cancer detection and monitoring. Founded in 2007 and headquartered in San Diego, California, the company focuses on the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from blood samples. Biocept’s proprietary liquid biopsy assays support biomarker testing for targeted therapy selection across multiple cancer types. By enabling real-time tumor characterization without invasive tissue biopsies, Biocept plays an important role in advancing precision oncology, improving treatment decision-making, and expanding access to personalized cancer diagnostics worldwide.

7. Illumina, Inc.

Illumina, Inc. is a global leader in next-generation sequencing (NGS) technology and a foundational enabler of the liquid biopsy market worldwide. Founded in 1998 and headquartered in San Diego, California, the company provides advanced sequencing systems, reagents, and bioinformatics solutions used to analyze circulating tumor DNA in liquid biopsy applications. Illumina’s platforms underpin cancer detection, precision oncology, and minimal residual disease monitoring across research and clinical settings. By continuously advancing sequencing accuracy, speed, and affordability, Illumina plays a pivotal role in expanding the clinical adoption and scalability of liquid biopsy–based diagnostics globally.

8. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a global life sciences leader and a major enabler of the liquid biopsy market through its expansive portfolio of molecular and genetic analysis technologies. Founded in 2006 and headquartered in Waltham, Massachusetts, the company provides advanced next-generation sequencing platforms, real-time PCR systems, sample preparation technologies, and clinical diagnostic solutions essential for liquid biopsy workflows. Its tools support cancer detection, genomic profiling, and minimal residual disease monitoring worldwide. Through continuous innovation, large-scale manufacturing, and global distribution, Thermo Fisher plays a critical role in accelerating precision oncology and non-invasive cancer diagnostics across research and clinical environments.

9. QIAGEN N.V.

QIAGEN N.V. is a global leader in molecular diagnostics and sample-to-insight solutions, playing a crucial role in enabling liquid biopsy testing worldwide. Founded in 1984 and headquartered in Venlo, the Netherlands, the company provides comprehensive workflows spanning sample preparation, PCR-based assays, next-generation sequencing solutions, and bioinformatics software. QIAGEN’s liquid biopsy portfolio supports the detection and analysis of circulating tumor DNA for cancer profiling, therapy selection, and disease monitoring. Through its strong regulatory portfolio, global laboratory partnerships, and continuous technology innovation, QIAGEN remains a key infrastructure provider in the expanding precision oncology and liquid biopsy market.

10. Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is a global life science research and clinical diagnostics company that plays a significant enabling role in the liquid biopsy market through its advanced digital PCR and molecular analysis technologies. Founded in 1952 and headquartered in Hercules, California, the company provides Droplet Digital PCR (ddPCR) systems widely used for the highly sensitive detection of circulating tumor DNA. Bio-Rad’s instruments, reagents, and diagnostic solutions support cancer research, clinical oncology testing, and minimal residual disease monitoring. Through continuous innovation and a strong global distribution network, Bio-Rad strengthens the analytical foundation of precision medicine worldwide.

Other Leading Global Liquid Biopsy Companies

• F. Hoffmann-La Roche AG
• Myriad Genetics, Inc.
• Agilent Technologies, Inc.
• Menarini Silicon Biosystems
• MDxHealth SA
• Epic Sciences, Inc.
• Sysmex Corporation
• ANGLE plc
• Exosome Diagnostics, Inc.
• Biodesix, Inc.

Conclusion

The global liquid biopsy market is entering a high-growth phase driven by the rising cancer burden, accelerating shift toward precision oncology, and rapid advances in molecular diagnostics. The increasing need for safe, repeatable, and real-time tumor monitoring is steadily displacing conventional tissue biopsies, reinforcing liquid biopsy as a clinical necessity rather than an alternative. Technological breakthroughs in next-generation sequencing, digital PCR, and bioinformatics continue to enhance sensitivity, scalability, and affordability, enabling broader clinical adoption. Supported by strong participation from leading diagnostics players and expanding regulatory approvals, the market is well positioned for sustained expansion, transforming early cancer detection, treatment personalization, and long-term disease management worldwide.